New epigallocatechin gallate (EGCG) nanocomplexes Co-assembled with 3-mercapto-1-hexanol and ß-lactoglobulin for improvement of antitumor activity

Journal of Biomedical Nanotechnology

Volumn 13, Issue 7, 2017, Pages 805-814

  Yang, Yuanyuan ^a   Jin, Peng ^a   Zhang, Xingcai ^b   Ravichandran, Nagaiya ^a   Ying, Hao ^a   Yu, Chenghuan ^c   Ying, Huazhong ^c   Xu, Yongquan ^d   Yin, Junfeng ^d   Wang, Kai ^a   Wu, Ming ^a   Du, Qizhen ^a  

^a Hejiang University   (China)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c INSTITUTE OF MATERIA MEDICA   (China)

^d BEIJING HOSPITAL   (China)

Author keywords

3 mercapto 1 Hexanol; Epigallocatechin 3 Gallate (EGCG); Nanocomplexes; Lactoglobulin; Tumor inhibition

Indexed keywords

ANTIOXIDANTS; BIOCHEMISTRY; CELL PROLIFERATION; TUMORS;

3-MERCAPTO-1-HEXANOL; EPIGALLOCATECHIN-3-GALLATE; LACTOGLOBULIN; NANOCOMPLEXES; TUMOR INHIBITION;

DRUG PRODUCTS;

3 MERCAPTO 1 HEXANOL; BETA LACTOGLOBULIN; EPIGALLOCATECHIN GALLATE; NANOCARRIER; UNCLASSIFIED DRUG;

A-375 CELL LINE; ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CACO-2 CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; LIVER TOXICITY; MELANOMA; MOUSE; MSTO-211H CELL LINE; NONHUMAN; PARTICLE SIZE; SUSTAINED DRUG RELEASE; TE-1 CELL LINE; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL; TUMOR GROWTH; ZETA POTENTIAL;

EID: 85034586253     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2017.2400     Document Type: Article

References (52)

1. B. Frei and J. V. Higdon, Antioxidant activity of tea polyphenols in vivo: Evidence from animal studies. J. Nutr. 133, 3275S (2003).
2. V. Crespy and G. Williamson, Review of the health effects of green tea catechins in in vivo animal models. J. Nutr. 134, 3431S (2004).
3. J. A. Vita, Tea consumption and cardiovascular disease: Effects on endothelial function. J. Nutr. 133, 3293S (2003).
4. M. S. Butt and M. T. Sultan, Green tea: Nature's defense against malignancies. Crit. Rev. Food Sci. Nutr. 49, 463 (2009).
5. I. A. Siddiqui, D. J. Bharali, M. Nihal, V. M. Adhami, N. Khan, J. C. Chamcheu, M. I. Khan, S. Shabana, S. A. Mousa, and H. Mukhtar, Excellent anti-proliferative and pro-apoptotic effects of (-)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo. Nanomed. Nanotechnol. Biol. Med. 10, 1619 (2014).
6. G. J. Du, Z. Zhang, X. D. Wen, C. Yu, T. Calway, C. S. Yuan, and C. Z. Wang, Epigallocatechin gallate (egcg) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients 4, 1679 (2012).
7. A. Chowdhury, J. Sarkar, T. Chakraborti, P. K. Pramanik, and S. Chakraborti, Protective role of epigallocatechin-3-gallate in health and disease: A perspective. Biomed. Pharmacother. 78, 50 (2016).
8. S. Tsukamoto, K. Hirotsu, M. Kumazoe, Y. Goto, K. Sugihara, T. Suda, Y. Tsurudome, T. Suzuki, S. Yamashita, and Y. Kim, Green tea polyphenol EGCG induces lipid-raft clustering and apoptotic cell death by activating protein kinase C and acid sphingomyelinase through a 67 kDa laminin receptor in multiple myeloma cells. Biochem. J. 443, 525 (2012).
9. Y. Clement, Can green tea do that: A literature review of the clinical evidence. Prev. Med. 49, 83 (2009).
10. M. Carbonaro, G. Grant, and A. Pusztai, Evaluation of polyphenol bioavailability in rat small intestine. Eur. J. Nutr. 40, 84 (2001).
11. Q. Wang, H. Cheng, H. Peng, H. Zhou, P. Y. Li, and R. Langer, Non-genetic engineering of cells for drug delivery and cell-based therapy. Adv. Drug Del. Rev. 91, 125 (2015).
12. J. Cao, R. Wang, N. Gao, M. Li, X. Tian, W. Yang, Y. Ruan, C. Zhou, G. Wang, and X. Liu, A7RC peptide modified paclitaxel liposomes dually target breast cancer. Biomaterials Science 3, 1545 (2015).
13. J. E. Chung, S. Tan, J. G. Shu, N. Yongvongsoontorn, S. H. Kim, J. H. Lee, H. S. Choi, H. Yano, Z. Lang, and M. Kurisawa, Selfassembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy. Nat. Nanotechnol. 9, 907 (2013).
14. T. X. Nguyen, L. Huang, M. Gauthier, G. Yang, and Q. Wang, Recent advances in liposome surface modification for oral drug delivery. Nanomedicine 11, 1169 (2016).
15. M. H. Li, H. Yu, T. F. Wang, N. D. Chang, J. Q. Zhang, D. Du, M. F. Liu, S. L. Sun, R. Wang, and H. Q. Tao, Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo. J. Mater. Chem. B 2, 1619 (2014).
16. H. Peng, C. Wang, X. Xu, C. Yu, and Q. Wang, An intestinal Trojan horse for gene delivery. Nanoscale 7, 4354 (2015).
17. F. Jia, X. Liu, L. Li, S. Mallapragada, B. Narasimhan, and Q. Wang, Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J. Control. Release 172, 1020 (2013).
18. H. Zheng, L. Yin, X. Zhang, H. Zhang, R. Hu, Y. Yin, T. Qiu, X. Xiong, and Q. Wang, Redox sensitive shell and core crosslinked hyaluronic acid nanocarriers for tumor-targeted drug delivery. J. Biomed. Nanotechnol. 12, 1641 (2016).
19. C. D. Kanakis, I. Hasni, P. Bourassa, P. A. Tarantilis, M. G. Polissiou, and H. A. Tajmirriahi, Milk -lactoglobulin complexes with tea polyphenols. Food Chem. 127, 1046 (2011).
20. A. Shpigelman, G. Israeli, and Y. D. Livney, Thermallyinduced protein-polyphenol co-assemblies: Beta lactoglobulin-based nanocomplexes as protective nanovehicles for EGCG. Food Hydrocolloids 24, 735 (2010).
21. A. K. Srivastava, P. Bhatnagar, M. Singh, S. Mishra, P. Kumar, Y. Shukla, and K. C. Gupta, Synthesis of PLGA nanoparticles of tea polyphenols and their strong in vivo protective effect against chemically induced DNA damage. Int. J. Nanomed. 8, 1451 (2013).
22. P. Lestringant, A. Guri, ?I. Gülseren, P. Relkin, and M. Corredig, Effect of processing on physicochemical characteristics and bioefficacy of -lactoglobulin-epigallocatechin-3-gallate complexes. J. Agric. Food Chem. 62, 8357 (2014).
23. J. Di, J. Yu, Q. Wang, S. Yao, D. Suo, Y. Ye, M. Pless, Y. Zhu, Y. Jing, and Z. Gu, Ultrasound-triggered noninvasive regulation of blood glucose levels using microgels integrated with insulin nanocapsules. Nano. Research 10, 1393 (2017).
24. X. Zhang, H. Zhang, L. Yin, R. Hu, T. Qiu, Y. Yin, X. Xiong, H. Zheng, and Q. Wang, A pH-sensitive nanosystem based on carboxymethyl chitosan for tumor-targeted delivery of daunorubicin. J. Biomed. Nanotechnol. 12, 1688 (2016).
25. H. Peng, X. Liu, G. Wang, M. Li, K. M. Bratlie, E. Cochran and Q. Wang, Polymeric multifunctional nanomaterials for theranostics. J. Mater. Chem. B 3, 6856 (2015).
26. A. Demming, Big challenges and nanosolutions. Nanotechnology 22, 290201 (2011).
27. L. Liang, H. A. Tajmirriahi, and M. Subirade, Interaction of -Lactoglobulin with resveratrol and its biological implications. Biomacromolecules 9, 50 (2008).
28. H. C. Liu, W. L. Chen, and S. J. Mao, Antioxidant nature of bovine milk beta-lactoglobulin. J. Dairy Sci. 90, 547 (2007).
29. N. R. Unnadkat and R. J. Elias, Oxidative stability of (-)-epigallocatechin gallate in the presence of thiols. J. Agric. Food Chem. 60, 10815 (2012).
30. A. Shpigelman, Y. Cohen, and Y. Livney, Thermally-induced -lactoglobulin-EGCG nanovehicles: Loading, stability, sensory and digestive-release study. Food Hydrocolloids 29, 57 (2012).
31. B. Li, W. Du, J. Jin, and Q. Du, Preservation of (-)-epigallocatechin- 3-gallate antioxidant properties loaded in heat treated -lactoglobulin nanoparticles. J. Agric. Food Chem. 60, 3477 (2012).
32. A. Kumari, S. K. Yadav, Y. B. Pakade, B. Singh, and S. C. Yadav, Development of biodegradable nanoparticles for delivery of quercetin. Colloids Surf. B Biointerface 80, 184 (2010).
33. S. Shankar, L. Marsh, and R. K. Srivastava, EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin. Mol. Cell. Biochem. 372, 83 (2013).
34. Y. L. Su, K. L. Lai, Y. Huang, and Z. Y. Chen, Stability of tea theaflavins and catechins. Food Chem. 83, 189 (2003).
35. J. D. Lambert, M. J. Kennett, S. Sang, K. R. Reuhl, J. Ju, and C. S. Yang, Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem. Toxicol. 48, 409 (2010).
36. P. Scheidegger, W. Weiglhofer, S. Suarez, B. Kaserhotz, R. Steiner, K. Ballmerhofer, and R. Jaussi, Vascular endothelial growth factor (VEGF) and its receptors in tumor-bearing dogs. Biol. Chem. 380, 1449 (1999).
37. S. Trompezinski, A. Denis, D. Schmitt, and J. Viac, Comparative effects of polyphenols from green tea (EGCG) and soybean (genistein) on VEGF and IL-8 release from normal human keratinocytes stimulated with the proinflammatory cytokine TNFalpha. Arch. Dermatol. Res. 295, 112 (2003).
38. R. H. Schwartz, Costimulation of T lymphocytes: Minireview the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71, 1065 (1992).
39. S. Akira, T. Hirano, T. Taga, and T. Kishimoto, Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J. 4, 2860 (1990).
40. J. Hong, H. Lu, X. Meng, J. H. Ryu, Y. Hara, and C. S. Yang, Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res. 62, 7241 (2002).
41. G. Q. Tang, T. Q. Yan, G. Wei, T. T. Ren, C. L. Peng, Z. Hui, X. C. Lu, F. L. Zhao, and X. Han, (-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells. J. Cancer Res. Clin. Oncol. 136, 1179 (2010).
42. G. Mazzanti, F. Mennitiippolito, P. A. Moro, F. Cassetti, R. Raschetti, C. Santuccio, and S. Mastrangelo, Hepatotoxicity from green tea: A review of the literature and two unpublished cases. Eur. J. Clin. Pharmacol. 65, 331 (2009).
43. I. A. Siddiqui, V. M. Adhami, N. Ahmad, and H. Mukhtar, Nanochemoprevention: Sustained release of bioactive food components for cancer prevention. Nutr. Cancer 62, 883 (2010).
44. Y. H. Bae and K. Park, Targeted drug delivery to tumors: Myths, reality and possibility. J. Control. Release 153, 198 (2011).
45. J. Qi, Y. Xu, W. Liang, D. Fei, X. Wu, and J. Jin, Progress in the preparation technologies and active improvement of EGCG nanocarriers. J. Tea Sci. 37, 337 (2017).
46. R. Shukla, N. Chanda, A. Zambre, A. Upendran, K. Katti, R. R. Kulkarni, S. K. Nune, S. W. Casteel, C. J. Smith, and J. Vimal, Laminin receptor specific therapeutic gold nanoparticles (198AuNPEGCg) show efficacy in treating prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 109, 12426 (2012).
47. M. Singh, P. Bhatnagar, S. Mishra, P. Kumar, Y. Shukla, and K. C. Gupta, PLGA-encapsulated tea polyphenols enhance the chemotherapeutic efficacy of cisplatin against human cancer cells and mice bearing Ehrlich ascites carcinoma. Int. J. Nanomed. 10, 6789 (2014).
48. S. Narayanan, U. Mony, M. Koyakutty, B. Paul-Prasanth, and D. Menon, Sequential release of Epigallocatechin gallate and Paclitaxel from PLGA-Casein core/shell nanoparticles sensitizes drugresistant breast cancer cells. Nanomed. Nanotechnol. Biol. Med. 11, 1399 (2015).
49. B. Liao, H. Ying, C. Yu, Z. Fan, W. Zhang, J. Shi, H. Ying, N. Ravichandran, Y. Xu, and J. Yin, (-)-Epigallocatechin gallate (EGCG)-nanoethosomes as a transdermal delivery system for docetaxel to treat implanted human melanoma cell tumors in mice. Int. J. Pharm. 512, 22 (2016).
50. X. Zhang, Tea and cancer prevention. Journal of Cancer Research Updates 4, 65 (2015).
51. V. Vergaro, F. Scarlino, C. Bellomo, R. Rinaldi, D. Vergara, M. Maffia, F. Baldassarre, G. Giannelli, X. Zhang, Y. Lvov, and S. Leporatti, Drug-loaded polyelectrolyte microcapsules for sustained targeting of cancer cells. Advanced Drug Delivery Reviews 63, 847 (2011).
52. D. Vergara, C. Bellomo, X. Zhang, V. Vergaro, A. Tinelli, V. Lorusso, R. Rinaldi, Y. Lvov, S. Leporatti, and M. Maffia, Lapatinib/paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer. Nanomedicine: Nanotechnology, Biology and Medicine 8, 891 (2012).